[go: up one dir, main page]

HRP20201399T1 - Novi modulatori i postupci njihove uporabe - Google Patents

Novi modulatori i postupci njihove uporabe Download PDF

Info

Publication number
HRP20201399T1
HRP20201399T1 HRP20201399TT HRP20201399T HRP20201399T1 HR P20201399 T1 HRP20201399 T1 HR P20201399T1 HR P20201399T T HRP20201399T T HR P20201399TT HR P20201399 T HRP20201399 T HR P20201399T HR P20201399 T1 HRP20201399 T1 HR P20201399T1
Authority
HR
Croatia
Prior art keywords
seq
residues
variable region
antibody
chain variable
Prior art date
Application number
HRP20201399TT
Other languages
English (en)
Inventor
Orit Foord
Scott J. Dylla
Robert A. Stull
Alex Bankovich
Alexandra Leida Liana LAZETIC
Jeffrey Bernstein
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/050451 external-priority patent/WO2012031280A2/en
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of HRP20201399T1 publication Critical patent/HRP20201399T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (19)

1. Kimerno, CDR-kalemljeno, humanizirano ili rekombinantno ljudsko protutijelo, ili njegov fragment koji veže antigen, naznačeno time, da se specifično veže na ljudski PTK7 i pritom obuhvaća varijabilne regije lakog i teškog lanca, pri čemu: (a) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 24-34 od SEQ ID NO:62 za VL CDR1, ostaci 50-56 od SEQ ID NO:62 za VL CDR2 i ostaci 89-97 od SEQ ID NO:62 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 31-35 od SEQ ID NO:63 za VH CDR1, ostaci 50-65 od SEQ ID NO:63 za VH CDR2 i ostaci 95-102 od SEQ ID NO:63 za VH CDR3, pri čemu je CDR-numeriranje u skladu s Kabat shemom; (b) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 23-34 od SEQ ID NO:62 za VL CDR1, ostaci 50-56 od SEQ ID NO:62 za VL CDR2 i ostaci 89-97 od SEQ ID NO:62 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 26-32 od SEQ ID NO:63 za VH CDR1, ostaci 50-58 od SEQ ID NO:63 za VH CDR2 i ostaci 95-102 od SEQ ID NO:63 za VH CDR3, pri čemu je CDR-numeriranje u skladu s Chothia shemom; ili (c) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-36 od SEQ ID NO:62 za VL CDR1, ostaci 46-55 od SEQ ID NO:62 za VL CDR2 i ostaci 89-96 od SEQ ID NO:62 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-35 od SEQ ID NO:63 za VH CDR1, ostaci 47-58 od SEQ ID NO:63 za VH CDR2 i ostaci 93-101 od SEQ ID NO:63 za VH CDR3, pri čemu je CDR-numeriranje u skladu s MacCallum shemom.
2. Kimerno, CDR-kalemljeno, humanizirano ili rekombinantno ljudsko protutijelo, ili njegov fragment koji veže antigen, naznačeno time, da se specifično veže na ljudski PTK7 i pritom obuhvaća varijabilne regije lakog i teškog lanca, pri čemu: (a) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 24-34 od SEQ ID NO:64 za VL CDR1, ostaci 50-56 od SEQ ID NO:64 za VL CDR2 i ostaci 89-97 od SEQ ID NO:64 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 31-35 od SEQ ID NO:65 za VH CDR1, ostaci 50-65 od SEQ ID NO:65 za VH CDR2 i ostaci 95-102 od SEQ ID NO:65 za VH CDR3, pri čemu je CDR-numeriranje u skladu s Kabat shemom; (b) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 23-34 od SEQ ID NO:64 za VL CDR1, ostaci 50-56 od SEQ ID NO:64 za VL CDR2 i ostaci 89-97 od SEQ ID NO:64 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 26-32 od SEQ ID NO:65 za VH CDR1, ostaci 50-58 od SEQ ID NO:65 za VH CDR2 i ostaci 95-102 od SEQ ID NO:65 za VH CDR3, pri čemu je CDR-numeriranje u skladu s Chothia shemom; ili (c) varijabilna regija lakog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-36 od SEQ ID NO:64 za VL CDR1, ostaci 46-55 od SEQ ID NO:64 za VL CDR2 i ostaci 89-96 od SEQ ID NO:64 za VL CDR3, i varijabilna regija teškog lanca obuhvaća tri CDR-a koji su predstavljeni kao ostaci 30-35 od SEQ ID NO:65 za VH CDR1, ostaci 47-58 od SEQ ID NO:65 za VH CDR2 i ostaci 93-101 od SEQ ID NO:65 za VH CDR3, pri čemu je CDR-numeriranje u skladu s MacCallum shemom.
3. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1 ili 2, naznačeno time, da obuhvaća: (a) varijabilnu regiju lakog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:62 i varijabilnu regiju teškog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:63; ili (b) varijabilnu regiju lakog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:64 i varijabilnu regiju teškog lanca koja posjeduje aminokiselinsku sekvencu koja je najmanje 60% identična kao SEQ ID NO:65.
4. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1, naznačeno time, da obuhvaća varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:62 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:63.
5. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 2, naznačeno time, da obuhvaća varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:64 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:65.
6. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time, da je to neutralizirajuće, iscrpljujuće protutijelo, i/ili je internalizirajuće protutijelo.
7. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time, da se specifično veže na PTK7 izooblik koji je odabran iz skupine koju čine: izooblik a, izooblik b, izooblik c i izooblik d.
8. Konjugat protutijela, naznačen time, da obuhvaća protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, gdje je to protutijelo konjugirano, povezano, ili na neki drugi način udruženo sa citotoksičnim sredstvom.
9. Farmaceutski pripravak, naznačen time, da obuhvaća protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela u skladu s patentnim zahtjevom 8.
10. Nukleinska kiselina, naznačena time, da kodira varijabilnu regiju teškog lanca i/ili varijabilnu regiju lakog lanca protutijela ili njegovog fragmenta koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7.
11. Vektor ili stanica domaćina, naznačeni time, da sadrže nukleinsku kiselinu u skladu s patentnim zahtjevom 10.
12. Stanica, naznačena time, da obuhvaća protutijelo koje se specifično veže na ljudski PTK7, pri čemu stanica obuhvaća jednu ili više nukleinskih kiselina koje kodiraju sljedeće: (a) varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:62 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:63; ili (b) varijabilnu regiju lakog lanca koja je predstavljena kao SEQ ID NO:64 i varijabilnu regiju teškog lanca koja je predstavljena kao SEQ ID NO:65.
13. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela prema patentnom zahtjevu 8, naznačeni time, da se upotrebljavaju kao farmaceutski proizvod.
14. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time, da se upotrebljava u detektiranju, dijagnosticiranju ili nadgledanju poremećaja koji je povezan s PTK7 kod pojedinca, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, gdje je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
15. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela prema patentnom zahtjevu 8, naznačeni time, da se upotrebljavaju u liječenju poremećaja koji je povezan s PTK7 kod pojedinca, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, dok je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
16. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, ili konjugat protutijela prema patentnom zahtjevu 8, naznačeni time, da se upotrebljavaju u smanjivanju frekvencije stanica koje iniciraju tumor kod pojedinca.
17. Protutijelo ili njegov fragment koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time, da se upotrebljava u postupku in vivo za detektiranje, dijagnosticiranje ili nadgledanje poremećaja koji je povezan s PTK7 kod pojedinca, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, gdje je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
18. Postupak in vivo za detektiranje, dijagnosticiranje ili nadgledanje poremećaja koji je povezan s PTK7, naznačen time, da se provodi uporabom protutijela ili njegovog fragmenta koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu je poremećaj koji je povezan s PTK7 proliferativni poremećaj, gdje je to opcionalno neoplastični poremećaj koji obuhvaća čvrsti tumor, kao što je rak dojke, rak jajnika, kolorektalni rak, rak gušterače, rak pluća ili rak kože.
19. Protutijelo ili njegov fragment koji veže antigen, za uporabu u skladu s bilo kojim od patentnih zahtjeva 14 do 15 ili 17, ili konjugat protutijela za uporabu u skladu s patentnim zahtjevom 15, ili postupak prema patentnom zahtjevu 18, naznačeni time, da poremećaj koji je povezan s PTK7 je rak.
HRP20201399TT 2011-02-18 2012-02-17 Novi modulatori i postupci njihove uporabe HRP20201399T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161444614P 2011-02-18 2011-02-18
PCT/US2011/050451 WO2012031280A2 (en) 2010-09-03 2011-09-02 Identification and enrichment of cell subpopulations
EP12705776.8A EP2675827B1 (en) 2011-02-18 2012-02-17 Novel modulators and methods of use
PCT/US2012/025726 WO2012112943A1 (en) 2011-02-18 2012-02-17 Novel modulators and methods of use

Publications (1)

Publication Number Publication Date
HRP20201399T1 true HRP20201399T1 (hr) 2020-11-27

Family

ID=46672972

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201399TT HRP20201399T1 (hr) 2011-02-18 2012-02-17 Novi modulatori i postupci njihove uporabe

Country Status (32)

Country Link
US (3) US9409995B2 (hr)
EP (2) EP2675827B1 (hr)
JP (2) JP6296796B2 (hr)
KR (1) KR102022734B1 (hr)
CN (2) CN107056945A (hr)
AR (1) AR085281A1 (hr)
AU (3) AU2012219313C1 (hr)
BR (1) BR112013021134B1 (hr)
CA (1) CA2827637C (hr)
CO (1) CO6791571A2 (hr)
CY (1) CY1123551T1 (hr)
DK (1) DK2675827T3 (hr)
ES (1) ES2829206T3 (hr)
HR (1) HRP20201399T1 (hr)
HU (1) HUE050657T2 (hr)
IL (3) IL228018A (hr)
LT (1) LT2675827T (hr)
MX (1) MX356434B (hr)
MY (1) MY173880A (hr)
PE (2) PE20181076A1 (hr)
PH (2) PH12013501710A1 (hr)
PL (1) PL2675827T3 (hr)
PT (1) PT2675827T (hr)
RS (1) RS60841B1 (hr)
RU (2) RU2627176C2 (hr)
SA (1) SA112330278B1 (hr)
SG (2) SG192816A1 (hr)
SI (1) SI2675827T1 (hr)
SM (1) SMT202000556T1 (hr)
TW (2) TWI624476B (hr)
WO (1) WO2012112943A1 (hr)
ZA (1) ZA201306958B (hr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
JP6240504B2 (ja) 2010-09-03 2017-11-29 アッヴィ・ステムセントルクス・エル・エル・シー 細胞亜集団の同定及び濃縮
US20130061340A1 (en) * 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
JP6454547B2 (ja) 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
WO2014089493A1 (en) * 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
CA2907429A1 (en) * 2013-07-04 2015-01-08 Rheinisch-Westfaelische Technische Hochschule Aachen A new fusion protein to target and treat acute myloid leukemia cells
CN105980852B (zh) * 2014-04-17 2019-07-26 深圳迈瑞生物医疗电子股份有限公司 细胞分析方法和系统、装置
ES2856927T3 (es) 2014-04-30 2021-09-28 Pfizer Conjugados de fármaco-anticuerpo anti-PTK7
BR112019019595A2 (pt) * 2017-03-23 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
TWI776024B (zh) 2018-02-28 2022-09-01 美商輝瑞大藥廠 Il-15變體及其用途
WO2019224715A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for cd3 and uses thereof
TWI803637B (zh) 2018-05-23 2023-06-01 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
US12247084B2 (en) 2018-06-14 2025-03-11 2Seventy Bio, Inc. Anti-BCMA CAR antibodies, conjugates, and methods of use
WO2020014175A1 (en) * 2018-07-10 2020-01-16 Children's Medical Center Corporation Methods and compositions for analyzing immortalized megakaryocyte progenitor cell lines and platelet-like particles derived therefrom
WO2020095248A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2021127007A1 (en) * 2019-12-16 2021-06-24 Bluebird Bio, Inc. Anti-bcma car antibodies, conjugates, and methods of use
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
WO2021124096A1 (en) 2019-12-18 2021-06-24 Pfizer Inc. Once daily cancer treatment regimen with a prmt5 inhibitor
JP7515204B2 (ja) * 2020-02-27 2024-07-12 エスアンドティー バイオメッド カンパニー リミテッド マトリックスメタロプロテアーゼ１のモノクローナル抗体、その検出キット及び検出方法
WO2021181233A2 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
EP4149975A2 (en) 2020-05-13 2023-03-22 Pfizer Inc. Methods, therapies and uses for treating cancer
KR102678735B1 (ko) * 2020-07-16 2024-06-26 연세대학교 산학협력단 Ptk7에 특이적으로 결합하는 항체 및 이의 용도
EP4182346A1 (en) 2020-07-17 2023-05-24 Pfizer Inc. Therapeutic antibodies and their uses
KR20230069181A (ko) 2020-09-14 2023-05-18 화이자 인코포레이티드 암 치료를 위한 방법, 요법 및 용도
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
WO2023108101A1 (en) * 2021-12-09 2023-06-15 Emory University Antibodies that inhibit glycoprotein ib-ix mediated platelet signaling and uses in managing bleeding conditions
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
KR20250010064A (ko) 2022-06-17 2025-01-20 화이자 인코포레이티드 Il-12 변이체, 항-pd1 항체, 융합 단백질, 및 그의 용도
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
IL317957A (en) 2022-07-05 2025-02-01 Pfizer PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
CN120019079A (zh) * 2022-10-14 2025-05-16 Jsr株式会社 抗体及其用途
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
CN120916781A (zh) * 2023-03-23 2025-11-07 百奥赛图(北京)医药科技股份有限公司 抗体及其用途
CN121079303A (zh) 2023-04-05 2025-12-05 辉瑞大药厂 吡啶并[4,3-d]嘧啶化合物
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
TW202523350A (zh) 2023-08-10 2025-06-16 美商輝瑞股份有限公司 治療癌症之方法，療法及用途
WO2025094035A1 (en) 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265551A (en) 1977-07-13 1981-05-05 U.S. Philips Corporation Drive for transporting and reversing an ink ribbon, and for withdrawing the printing head in printing devices
US4111824A (en) 1977-07-21 1978-09-05 Gulf Research & Development Co. Liquid dielectric composition based on a fraction derived from the alkylation product of benzene with ethylene
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP0732402A3 (en) 1990-12-14 1997-05-21 Cell Genesys Inc Chimeric chains for transduction of receptor-linked signaling pathways
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
ES2223040T3 (es) 1991-04-10 2005-02-16 The Scripps Research Institute Bibliotecas de receptor heterodimerilo que usan fagemidos.
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
EP0749475A4 (en) 1992-08-26 1997-05-07 Harvard College USE OF CYTOKINE IP-10 AS ANTI-TUMOR AGENT
RO118524B1 (ro) 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Metoda pentru tratarea unei tulburari legata de celulele b
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
JP4441112B2 (ja) 1997-11-03 2010-03-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 新脈管形成および腫瘍増殖のインヒビターであるｖｅｇｉ
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
CA2359067C (en) 1999-01-15 2017-03-14 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
DK2236152T3 (da) 2000-04-12 2014-07-07 Novozymes Biopharma Dk As Albuminfusionsproteiner
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP3690043A1 (en) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Antibody composition-producing cell
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
EP1461423B1 (en) 2001-12-03 2008-05-14 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2003217930A1 (en) 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
EP1553963A4 (en) 2002-09-24 2006-05-03 Burnham Inst NEW MEANS FOR MODULATING EPH RECEPTOR ACTIVITY
DK2364996T3 (en) 2002-09-27 2017-02-06 Xencor Inc Optimized Fc variants and methods for their formation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
ATE516047T1 (de) 2003-05-09 2011-07-15 Diadexus Inc Ovr110-antikörperzusammensetzungen und anwendungsverfahren
RU2366716C2 (ru) * 2003-10-24 2009-09-10 Эсбатек Аг Способ идентификации и/или проверки ингибиторов рецепторных тирозинкиназ
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
WO2006023420A2 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
US8222253B2 (en) 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
EP1928912A4 (en) 2005-09-07 2010-02-24 Medimmune Inc EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
SI1957539T1 (sl) 2005-12-08 2013-05-31 Medarex, Inc. Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba
EP1973574B1 (en) 2005-12-30 2014-04-02 Institut Gustave Roussy Use of inhibitors of scinderin and/or of ephrin-a1 for treating tumors
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
EP2024392A2 (en) 2006-03-17 2009-02-18 Biogen Idec MA, Inc. Stabilized polypeptide compositions
WO2007145901A1 (en) 2006-06-06 2007-12-21 University Of Tennessee Research Foundation Compositions enriched in neoplastic stem cells and methods comprising same
PT3207941T (pt) 2006-09-07 2020-04-02 Scott & White Memorial Hospital Métodos e composições baseados em conjugados de toxina diftérica-interleucina-3
CA2675521C (en) 2007-01-22 2016-04-26 Raven Biotechnologies Human cancer stem cells
WO2008149803A1 (ja) * 2007-06-06 2008-12-11 The University Of Tokyo 表面抗原マーカーを用いた急性リンパ性白血病における癌幹細胞の分離同定方法
EP2190481B1 (en) 2007-07-17 2014-12-24 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
CN101842116A (zh) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 结合igf-1r多个表位的组合物
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
WO2009070767A2 (en) * 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
KR20100101124A (ko) 2007-11-30 2010-09-16 브리스톨-마이어스 스큅 컴퍼니 단백질 티로신 키나제 ７ (ｐｔｋ７)에 대한 모노클로날 항체 파트너 분자 컨쥬게이트
KR101123130B1 (ko) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
US8384551B2 (en) 2008-05-28 2013-02-26 MedHab, LLC Sensor device and method for monitoring physical stresses placed on a user
US8197809B2 (en) 2008-06-25 2012-06-12 Korea Research Institute Of Bioscience And Biotechnology CD9-specific human antibodies
WO2010037134A2 (en) 2008-09-29 2010-04-01 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
CA2748757A1 (en) * 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US8788213B2 (en) 2009-01-12 2014-07-22 Intrexon Corporation Laser mediated sectioning and transfer of cell colonies
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
FR2964148A1 (fr) 2010-08-30 2012-03-02 Peugeot Citroen Automobiles Sa Boite de degazage destinee au circuit de refroidissement d'un moteur thermique de vehicule automobile
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
JP6240504B2 (ja) 2010-09-03 2017-11-29 アッヴィ・ステムセントルクス・エル・エル・シー 細胞亜集団の同定及び濃縮
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
EP2446895A1 (en) 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
ES2856927T3 (es) * 2014-04-30 2021-09-28 Pfizer Conjugados de fármaco-anticuerpo anti-PTK7
EP3209334A2 (en) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Also Published As

Publication number Publication date
NZ615285A (en) 2015-09-25
JP2014511179A (ja) 2014-05-15
PL2675827T3 (pl) 2021-01-25
PT2675827T (pt) 2020-10-29
TW201800421A (zh) 2018-01-01
KR102022734B1 (ko) 2019-09-19
SG10201603926SA (en) 2016-07-28
LT2675827T (lt) 2020-10-26
CA2827637C (en) 2020-08-11
IL254062A0 (en) 2017-10-31
US20160272723A1 (en) 2016-09-22
BR112013021134A2 (pt) 2016-11-29
US20180162952A1 (en) 2018-06-14
MX2013009541A (es) 2014-04-30
AU2012219313A1 (en) 2013-05-02
PE20181076A1 (es) 2018-07-04
US10836831B2 (en) 2020-11-17
CN103547597A (zh) 2014-01-29
MY173880A (en) 2020-02-26
TWI696635B (zh) 2020-06-21
CN103547597B (zh) 2017-03-15
RU2627176C2 (ru) 2017-08-03
SA112330278B1 (ar) 2015-10-09
AU2012219313B2 (en) 2017-02-02
CO6791571A2 (es) 2013-11-14
ZA201306958B (en) 2022-03-30
BR112013021134B1 (pt) 2022-12-27
TW201309729A (zh) 2013-03-01
NZ708615A (en) 2017-02-24
TWI624476B (zh) 2018-05-21
IL228018A (en) 2017-09-28
PH12018500452A1 (en) 2019-11-18
US9914784B2 (en) 2018-03-13
RU2013141976A (ru) 2015-03-27
CY1123551T1 (el) 2022-03-24
EP2675827A1 (en) 2013-12-25
EP3763388A1 (en) 2021-01-13
BR112013021134A8 (pt) 2017-07-11
CN107056945A (zh) 2017-08-18
KR20140018905A (ko) 2014-02-13
US20140105888A1 (en) 2014-04-17
IL254062B (en) 2018-11-29
AU2017202934A1 (en) 2017-05-25
AR085281A1 (es) 2013-09-18
DK2675827T3 (da) 2020-09-07
US9409995B2 (en) 2016-08-09
ES2829206T3 (es) 2021-05-31
AU2019201258A1 (en) 2019-03-14
PH12013501710A1 (en) 2013-10-07
MX356434B (es) 2018-05-29
JP6296796B2 (ja) 2018-03-28
WO2012112943A1 (en) 2012-08-23
IL228018A0 (en) 2013-09-30
PE20141028A1 (es) 2014-08-30
CA2827637A1 (en) 2012-08-30
SG192816A1 (en) 2013-09-30
JP2018104409A (ja) 2018-07-05
HUE050657T2 (hu) 2021-01-28
AU2012219313C1 (en) 2017-05-25
IL263020A (en) 2018-12-31
EP2675827B1 (en) 2020-08-05
SMT202000556T1 (it) 2020-11-10
RS60841B1 (sr) 2020-10-30
SI2675827T1 (sl) 2020-11-30
RU2017126476A (ru) 2019-01-31

Similar Documents

Publication Publication Date Title
HRP20201399T1 (hr) Novi modulatori i postupci njihove uporabe
JP2014511179A5 (hr)
ES2686693T3 (es) Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones
ES2566602T3 (es) Anticuerpos anti-ErbB3
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2017500028A5 (hr)
JP2016513664A5 (hr)
RU2019118359A (ru) Антитело к cd73 человека
JP2016531915A5 (hr)
HRP20191169T1 (hr) Konjugati antidll3-protutijelo-pbd i njihove uporabe
JP2016536020A5 (hr)
HRP20211444T1 (hr) Anti-dll3 antitijelo
IL295230A (en) Combination therapy with anti-cd73 antibodies
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
JP2018127469A5 (hr)
RU2014138041A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2016538318A5 (hr)
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2018527919A5 (hr)
JP2014534806A5 (hr)
RU2016145277A (ru) Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака
RU2016100892A (ru) Антитела против tweakr и их применение
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
JP2017535257A5 (hr)
IL278574B1 (en) Compounds acting on glycans and methods of using them